Xu, Q., Yuanyuan, L., Jiejing, Z., Jian, L., Qingyu, L., Lingya, C., . . . Wei, Y. (2021). Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china. Cost Eff Resour Alloc.
Chicago-стиль цитированияXu, Qiaoping, et al. "Cost-effectiveness of Paclitaxel, Doxorubicin, Cyclophosphamide and Trastuzumab Versus Docetaxel, Cisplatin and Trastuzumab in New Adjuvant Therapy of Breast Cancer in China." Cost Eff Resour Alloc 2021.
MLA-цитированиеXu, Qiaoping, et al. "Cost-effectiveness of Paclitaxel, Doxorubicin, Cyclophosphamide and Trastuzumab Versus Docetaxel, Cisplatin and Trastuzumab in New Adjuvant Therapy of Breast Cancer in China." Cost Eff Resour Alloc 2021.